The bill, which would prohibit the sale of highly concentrated sodium nitrite, now heads to the Senate. If passed, the bill would make Washington the fourth state in the nation to ban the chemical.

The Washington state House of Representatives passed a bill aimed at outlawing a poison that dozens of young people have used ...

OLYMPIA, Wash. — Washington state legislators are considering a bill that would prohibit the sale of highly concentrated sodium nitrite, a chemical compound that has been linked to multiple ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Chemtrade Logistics Income Fund (OTCMKTS:CGIFF – Get Free Report) traded up 0.6% during mid-day trading on Monday . The stock traded as high as $7.12 and last traded at $7.12. Approximately 3,158 ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. Get real-time earnings ...

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

Investing.com -- Merck &Company Inc (NYSE:MRK) shares tumbled more than 10% Tuesday after reporting mixed fourth-quarter results, with earnings falling short of expectations, revenue surpassing ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.